Setipiprant
- Generic Name
- Setipiprant
- Drug Type
- Small Molecule
- Chemical Formula
- C24H19FN2O3
- CAS Number
- 866460-33-5
- Unique Ingredient Identifier
- BHF20LA2GM
- Background
Setipiprant has been investigated for the treatment of Seasonal Allergic Rhinitis.
A Safety and Efficacy Study of Setipiprant Tablets in Androgenetic Alopecia in Males
- First Posted Date
- 2016-05-24
- Last Posted Date
- 2019-04-05
- Lead Sponsor
- Allergan
- Target Recruit Count
- 169
- Registration Number
- NCT02781311
- Locations
- ๐บ๐ธ
DeNova Research, Chicago, Illinois, United States
๐บ๐ธCleveland Clinic, Dept of Dermatology, Cleveland, Ohio, United States
๐บ๐ธHeartland Research Associates, LLC, Wichita, Kansas, United States
A Study to Assess the Tolerability, Safety, Pharmacodynamics, and Pharmacokinetics of Ascending Single Doses (Including Food Interaction) and Ascending Multiple Doses of ACT-453859, and Multiple Doses of Setipiprant (ACT-129968)
- Conditions
- Healthy
- Interventions
- Drug: ACT-453859 1 mgDrug: ACT-453859 3 mgDrug: ACT-453859 10 mgDrug: ACT-453859 30mgDrug: ACT-453859 100 mgDrug: ACT-453859 300 mgDrug: ACT-453859 800 mgOther: Placebo
- First Posted Date
- 2015-03-06
- Last Posted Date
- 2018-07-10
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 88
- Registration Number
- NCT02381496
Efficacy, Safety, and Tolerability Study of ACT-129968 in Patients With Seasonal Allergic Rhinitis
- Conditions
- Seasonal Allergic Rhinitis
- Interventions
- First Posted Date
- 2011-12-02
- Last Posted Date
- 2018-09-28
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 630
- Registration Number
- NCT01484119
- Locations
- ๐บ๐ธ
Clinical Investigative Site 7903, New Braunfels, Texas, United States
๐บ๐ธClinical Investigative Site 7905, Austin, Texas, United States
๐บ๐ธClinical Investigative Site 7901, San Antonio, Texas, United States
Study of ACT-129968 in Adult Patients With Seasonal Allergic Rhinitis
- Conditions
- Seasonal Allergic Rhinitis
- Interventions
- First Posted Date
- 2010-11-16
- Last Posted Date
- 2019-05-15
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 579
- Registration Number
- NCT01241214
- Locations
- ๐บ๐ธ
Clinical Investigative Site 7902, San Antonio, Texas, United States
๐บ๐ธClinical Investigative Site 7901, San Antonio, Texas, United States
๐บ๐ธClinical Investigative Site 7906, San Antonio, Texas, United States
Clinical Study to Explore the Efficacy of ACT-129968 in Patients With Partly Controlled Asthma
- First Posted Date
- 2010-10-21
- Last Posted Date
- 2018-07-09
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 438
- Registration Number
- NCT01225315
- Locations
- ๐ต๐ฑ
Clinical Investigative Site # 5501, Lodz, Poland
๐บ๐ธClinical Investigative Site # 6215, New Orleans, Louisiana, United States
๐บ๐ธClinical Investigative Site 6202, Knoxville, Tennessee, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.